Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLR 121125
- Development stage
- Phase 1
- Lead developer
- Cellectar Biosciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CLR 121125 is an investigational radiopharmaceutical developed by Cellectar Biosciences. It is a phospholipid drug conjugate (PDC) that utilizes iodine-125 as an Auger electron-emitting radioisotope, designed for targeted radiotherapy of solid tumors. The compound leverages Cellectar’s proprietary PDC platform to deliver the radioisotope directly into cancer cells, maximizing intracellular delivery and minimizing off-target effects. Auger emitters like iodine-125 are characterized by their extremely short emission range (a few nanometers), which allows for highly precise tumor cell killing with minimal damage to surrounding healthy tissue. Preclinical studies have demonstrated robust in vivo activity and tolerability in multiple animal models, including triple-negative breast cancer, lung cancer, and colorectal cancer. CLR 121125 has received IND clearance from the FDA and is set to enter Phase 1b/2a clinical trials in patients with triple-negative breast cancer[1][2][4][7].
- Brand names
- CLR 125CLR125CLR-125
- Other names
- CLR125CLR-125CLR 125
02
Targets
DNA
Beyond the preview
Go deeper on CLR 121125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLR 121125.